(lp0
S"Trading Options During Earnings in Alimera Sciences Inc  CML News - 21 hours ago We're going to examine buying and selling out of the money strangles in Alimera Sciences Inc and find out once and for all what the winning trades have been during earnings releases.Zacks: Analysts Set $3.00 Price Target for Alimera Sciences Inc  - Chaffey BreezeAlimera Sciences, Inc.  in-depth technical analysis - Post Analyst"
p1
aS"Alimera Sciences, Inc.  Looks Good: Stock Up 12.8% March 14, 2017 Zacks.com - Mar 14, 2017 Alimera Sciences, Inc. was a big mover last session, as the company saw its shares rise almost 13% on the day. The upside was driven by the company's improved fourth-quarter and full-year 2016 results."
p2
aS'Alimera Sciences: 2017 Outlook Seeking Alpha - Feb 10, 2017 Alimera had a big sequential jump in net sales in Q2 followed by a dip in Q3. The company explained on the Q3 call that Q2 sales were inflated by a distributor inventory buildup and that end-user demand was actually slightly higher in Q3 compared to Q2.'
p3
aS'ALIMERA SCIENCES, INC.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 1, 2017 Alimera Sciences, Inc.  is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial ... - GlobeNewswire Alimera Sciences Inc  Issues Quarterly Earnings Results, Misses ... - Chaffey Breeze'
p4
aS'Eye drug company Alimera Sciences mulls sale: sources Reuters - Dec 17, 2015 Alimera Sciences Inc, an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter.Alimera Sciences Inc  Stock is Up Amid Reaching Distribution Drug Deal ... - Independent Reporter'
p5
aS'Alimera Sciences: Insiders Buying This Biotech, Stock Sees Catalyst Seeking Alpha - Oct 12, 2015 Alimera Sciences  is a bio-pharmaceutical company on the Nasdaq with a market cap of $116 million. The company has developed a product called Iluvien, which was FDA approved in 2014 and made commercially available in the US, UK,&nbsp;...'
p6
aS'Alimera Sciences and Knight Therapeutics Announce Filing of New Drug ... Yahoo Finance - Feb 22, 2017 ATLANTA, GEORGIA and MONTREAL, QUEBEC-- - Alimera Sciences, Inc.  , a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc.What do Analysts Say about: Alimera Sciences, Inc.  - News OracleStock Movements Activity: Alimera Sciences, Inc.  - Is stories'
p7
aS"Alimera: Risks Reduced After Q2 Pre-Announcement Seeking Alpha - Jul 28, 2016 The company's market cap before today's jump was just around $50 million, which is very low considering Iluvien's potential."
p8
aS'Alimera Sciences Pre-Announces Record Second Quarter 2016 Revenue GlobeNewswire  - Jul 26, 2016 ATLANTA, July 26, 2016  -- Alimera Sciences , a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today pre-announced its revenue for the second quarter of 2016 and also ...'
p9
aS"Here's Why Cowen Upgraded Alimera Sciences Inc  Shares Smarter Analyst - Sep 16, 2016 With near-term financing overhang removed and more confident in Iluvien's sales growth, Cowen analyst Boris Peaker upgrades shares of Alimera Sciences Inc  from Market Perform to Outperform, while issuing a $3 price target, which&nbsp;...UPDATE: Cowen Sees Opportunity in Alimera Sciences  and Upgrades Stock ... - StreetInsider.com"
p10
a.